MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE

MAO/非人类灵长类动物中艾滋病疫苗的评价

• 批准号: 2600874
• 负责人: Randall J. Owens
• 金额: $ 13.63万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-06-30 至 1998-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2600874
• 关键词: AIDS vaccines; Macaca nemestrina; drug screening /evaluation; simian AIDSs; simian immunodeficiency virus

The HIV Preclinical Vaccine Development Master Agreement Program was initiated to enable the NIAID to provide resources to accelerate the development of promising vaccine approaches. Under this program, a series of vaccine studies have been initiated to e valuate candidate and prototype AIDS vaccines in nonhuman primates. These studies are designed to obtain more information about the efficacy and optimum presentation of candidate HIV vaccines that are in human Phase i clinical trials or proposed for such trials as well as prototype SIV vaccines of the same type as these HIV vaccines. Other vaccine studies will evaluate prototype HIV or SIV vaccines that offer novel presentation systems, may be capable of eliciting broadly cross-reactive immune responses, or have shown promising preliminary results. NIAID has initiated collaborative arrangements with researchers who have agreed to provide HIV and SIV vaccines for Immunization of nonhuman primates. In all of the vaccine studies, the nonhuman primates will be challenged after immunization to determine if protection from infection or from disease can be obtained. The contractors in Category B of the Master Agreement Program, including the contractor listed above, will provide, house and car for, immunize, and challenge the nonhuman primates for the various vaccine studies. The contractors will obtain sera, cells, and other appropriate samples from the animals in the studies, and will ship the samples, as appropriate, to contractors for evaluation of humoral immune responses, including neutralizing antibodies, for evaluation of cellular immune responses, and for virological assessment after challenge. The category B contractors will maintain a data base for each study they are conducting in order to follow the immunization protocol, virus challenge,a nd all the assay results for each monkey in the study.

HIV临床前疫苗开发主协议计划 发起的目的是使 NIAID 能够提供资源来加速 开发有前景的疫苗方法。 根据该计划，一系列 疫苗研究已启动以评估候选疫苗和原型 非人类灵长类动物的艾滋病疫苗。 这些研究旨在获得 有关候选人的功效和最佳表现的更多信息 处于人体 I 期临床试验或拟用于此类临床试验的 HIV 疫苗 试验以及与这些 HIV 相同类型的 SIV 疫苗原型 疫苗。 其他疫苗研究将评估 HIV 或 SIV 原型 提供新颖呈现系统的疫苗可能能够引发 广泛的交叉反应性免疫反应，或已显示出有希望的 初步结果。 NIAID 已与以下机构启动合作安排： 已同意提供 HIV 和 SIV 疫苗的研究人员 非人类灵长类动物的免疫。 在所有疫苗研究中， 非人类灵长类动物在免疫后将受到挑战以确定是否 可以获得免受感染或疾病的保护。 承包商 属于主协议计划的 B 类，包括承包商 上面列出的，将提供住房和汽车，免疫接种，并挑战 非人类灵长类动物用于各种疫苗研究。 承包商将 从动物身上获取血清、细胞和其他适当的样本 研究，并将酌情将样品运送给承包商 评估体液免疫反应，包括中和抗体， 用于评估细胞免疫反应和病毒学评估 挑战后。 B 类承包商将维护一个数据库 他们为跟踪免疫接种而进行的每项研究 实验方案、病毒攻击以及每只猴子的所有检测结果 学习。